Abstract
A simple, sensitive, and reproducible reversed-phase high-performance liquid chromatography (RP-HPLC) method, coupled with a photodiode array detector, was developed for the determination of rupatadine (RUPA) and its related substances in pharmaceutical dosage forms. Chromatographic separation was achieved on the Hypersil BDS (150 x 4.6 mm, 5 μm) column with a mobile phase containing a gradient mixture of a buffer (acetate buffer pH-6.0) and solvent (methanol). The eluted compounds were monitored at 264 nm for the related substances and assay, the flow rate was 1.0 mL/min, and the column oven temperature was maintained at 50°C. The developed method separated RUPA from its four known and three unknown impurities within 15.0 min. Rupatadine was subjected to the stress conditions of oxidative, acid, base, hydrolytic, thermal, and photolytic degradation. Rupatadine was found to degrade significantly under oxidative stress conditions, and degrade slightly under acid, base, hydrolytic, thermal, and photolytic stress conditions. All impurities were well-resolved from each other and from the main peak, showing the stability-indicating power of the method. The developed method was validated as per the International Conference on Harmonization (ICH) guidelines. The developed and validated RP-HPLC method is LC-MS compatible and can be explored for the identification of eluted unknown impurities of RUPA.
Highlights
Rupatadine fumarate (RUPAF) is 8-chloro-11-{1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene}-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (2E)-but-2-enedioate.RUPAF discovery, pre-clinical, and clinical development was performed by J
The spiked solution of RUPA (1000 μg/mL), IMP-A (5 μg/mL), IMP-B (5 μg/mL), Imp-C (5 μg/mL), Imp-D (5 μg/mL), and fumaric acid was subjected to separation by reversed-phase high-performance liquid chromatography (RP-high-performance liquid chromatography (HPLC))
Various types of mobile phase-A (MP-A) and mobile phase-B (MP-B) were studied to optimize the method, which are summarized in Table 1 with the associated observations
Summary
Rupatadine fumarate (RUPAF) is 8-chloro-11-{1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene}-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (2E)-but-2-enedioate.RUPAF discovery, pre-clinical, and clinical development was performed by J. There is no stability-indicating HPLC/UPLC method reported in the literature for the determination of RUPA and its impurities in solid oral dosage form. Felt necessary to develop a new rapid, stability-indicating method for the determination of the assay and impurities in RUPA solid oral dosage form.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
